PIK3CA and neuroblastoma: These observations, together with our findings in NB cells, support aberrant activation of PI3K/mTOR as part of a mechanism of acquired and/or innate resistance to kinase inhibitors and raise the possibility of adding PI3K/mTOR inhibitors to upstream kinase inhibitors at the outset of therapy.